Galmed Announces Positive Results from First 16 Patients in Liver Study

 -- Treatment with Aramchol 300mg BID reduced fibrosis progression measured by histology in 15 out of the 16 patients completed as of data cutoff --

-- 50% of the 16 patients showed fibrosis improvement by ≥1 stage, seen as early as 24 weeks --

--Data demonstrates that treatment with Aramchol 300mg BID resulted in clinically significant greater histological improvement than observed previously with Aramchol 600mg QD --

-- Data add to body of evidence from prior studies demonstrating the benefit of Aramchol for patients with histologically confirmed NASH and fibrosis and provides clinical support for the hypothesis that a higher daily dose will result in improved clinical benefit --

-- Data will be presented at a late-breaking poster presentation at The Liver Meeting Digital Experience 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will be held from November 12-15, 2021 --

Galmed's management team will host a conference call and webcast to provide an update on current developments with respect to its clinical programs for Aramchol including NASH Expert Insights on the ongoing Open-Label Part of the ARMOR study, and to discuss financial results for the quarter ended September 30, 2021 on November 8th @ 8.30am Eastern Time

Conference Call & Webcast:

Monday November 8, 2021, 8:30 AM ET

Toll Free: 1-877-425-9470
Toll/International: 1-201-389-0878
Israel Toll Free: 1 809 406 247
Conference ID: 13724243
Webcast: https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/47052/indexl.html

Replay Dial-In Numbers

Toll Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Pin Number: 13724243
Replay Start: Monday November 8, 2021, 11:30 AM ET
Replay Expiry: Monday November 22, 2021, 11:59 PM ET

https://finance.yahoo.com/news/galmed-announces-positive-results-first-141000189.html